Liraglutide vs SS-31
Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Liraglutide and SS-31 (also searched as SS-31 vs Liraglutide) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Liraglutide centers on metabolic, while SS-31 leans toward healing. On indexed research, SS-31 is ahead (Liraglutide: 26 studies, Human clinical; SS-31: 37, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Liraglutide is strongest for metabolic; SS-31 for healing.
- •Evidence: Liraglutide Human clinical (26 studies) vs SS-31 Human evidence (37).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
GLP-1 receptor agonist | Diabetes management
Mitochondrial protection | Heart and neuro health
Liraglutide vs SS-31: side-by-side
| Metric | Liraglutide | SS-31 |
|---|---|---|
| Class | Metabolic | Metabolic |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human evidence |
| Studies indexed | 26 | 37 |
| Research level | FDA Approved | Preclinical |
| Strongest effect | Metabolic & appetite | Healing & recovery |
| Healing & recovery | 1.0 | 4.0▲ |
| Muscle & body comp | 0.0 | 2.0▲ |
| Metabolic & appetite | 5.0▲ | 3.0 |
| Neuro & mood | 2.0 | 4.0▲ |
| Sleep & circadian | 0.0 | 1.0▲ |
| Inflammation & immune | 2.0 | 3.0▲ |
| Skin & aesthetics | 3.0▲ | 1.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Liraglutide | SS-31 |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Cardiolipin binding to stabilize mitochondrial membrane |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~13 hours | — |
| Time to peak | 8–12 hours | — |
| Duration of action | 24 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Liraglutide?
Liraglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), which is integral to glucose metabolism and appetite regulation. As a GLP-1 receptor agonist, liraglutide enhances insulin secretion in response to elevated blood glucose levels while inhibiting glucagon release, thereby contributing to lower blood sugar levels. Additionally, it slows gastric emptying and promotes feelings of fullness, which can aid in weight loss for individuals with obesity or type 2 diabetes.
Full Liraglutide profile, mechanism & studies →What is SS-31?
SS-31, also known as Elamipretide, is a peptide that has garnered attention for its potential role in mitochondrial protection and its implications in various health conditions, particularly those involving oxidative stress and mitochondrial dysfunction.
Full SS-31 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | SS-31 | 4.0/5 effect signal |
| Muscle | SS-31 | 2.0/5 effect signal |
| Metabolic | Liraglutide | 5.0/5 effect signal |
| Neuro | SS-31 | 4.0/5 effect signal |
| Sleep | SS-31 | 1.0/5 effect signal |
| Inflammation | SS-31 | 3.0/5 effect signal |
| Skin | Liraglutide | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Liraglutide and SS-31?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Liraglutide vs SS-31: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Liraglutide has 26 approved studies indexed (Human clinical), and SS-31 has 37 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Liraglutide or SS-31 better?
It depends on your goal. Liraglutide is strongest for metabolic; SS-31 for healing. SS-31 has more indexed studies (37). See the goal-by-goal breakdown above.
Is Liraglutide or SS-31 better for weight loss?
Liraglutide shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Liraglutide or SS-31 better for muscle?
SS-31 leads on the muscle & body-composition axis (2.0/5).
Which has more research, Liraglutide or SS-31?
Liraglutide has 26 approved studies indexed (Human clinical); SS-31 has 37 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Liraglutide and SS-31?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Liraglutide vs SS-31?
Liraglutide: no community-reported effects logged yet. SS-31: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Liraglutide or SS-31 FDA-approved?
Liraglutide is FDA-approved. SS-31 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is SS-31 better than Liraglutide?
For healing, SS-31 has the edge; for metabolic, Liraglutide does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.